Cargando...

Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality

Hypomethylating agents (HMA) with venetoclax is a new standard for older/unfit patients with acute myeloid leukemia (AML). However, it is unknown how HMA with venetoclax compare to intensive chemotherapy (IC) in patients who are ‘fit’ or ‘unfit’ for IC. We compared outcomes of older patients with ne...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Am J Hematol
Main Authors: Maiti, Abhishek, Qiao, Wei, Sasaki, Koji, Ravandi, Farhad, Kadia, Tapan M., Jabbour, Elias J., Daver, Naval G., Borthakur, Gautam, Garcia-Manero, Guillermo, Pierce, Sherry A., Montalbano, Kathryn S., Pemmaraju, Naveen, Naqvi, Kiran, Ohanian, Maro, Short, Nicholas J., Alvarado, Yesid, Takahashi, Koichi, Yilmaz, Musa, Jain, Nitin, Kornblau, Steven M., Andreeff, Michael, Bose, Prithviraj, Ferrajoli, Alessandra, Issa, Ghayas C., Masarova, Lucia, Thompson, Philip A., Rausch, Caitlin R., Ning, Jing, Kantarjian, Hagop M., DiNardo, Courtney D., Konopleva, Marina Y.
Formato: Artigo
Idioma:Inglês
Publicado: 2020
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8128145/
https://ncbi.nlm.nih.gov/pubmed/33264443
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.26061
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!